STUDY OBJECTIVE To assess the incidence of and risk factors associated with severe adverse events in elderly patients who used angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) after an acute myocardial infarction (AMI and hyperkalemia. The secondary outcome was discontinuation or suspension of ACEI/ARB therapy after a visit to a health care provider. The primary risk factors of interest were age, sex, race/ethnicity, and chronic kidney disease (CKD). Cumulative incidence curves and multivariable Fine-Gray proportional hazards models with 95% confidence intervals (CIs) were used with death as a competing risk in both intention-to-treat (ITT) and as-treated (AT) analyses. In the study cohort, 2.8% experienced ARF, 0.5% experienced hyperkalemia, and 63.7% discontinued ACEI/ARB therapy within 1 year after hospital discharge. Approximately half of the incidence of ARF and hyperkalemia occurred within 6 months after hospital discharge, but the cumulative incidence increased after 6 months. 
hyperkalemia (ITT HR 1.41, 95% CI 1.11-1.77), and ACEI/ARB therapy discontinuation or suspension (ITT HR 1.05, 95% CI 1.02-1.09). CONCLUSION We found a low incidence of ARF and hyperkalemia in elderly patients treated with ACEIs or ARBs after AMI hospitalization. However, a high rate of treatment discontinuation might prevent a higher rate of occurrence of these events. Long-term careful monitoring of severe adverse events and timely discontinuation of ACEIs or ARBs among elderly patients with advancing age and CKD after an AMI is warranted in clinical practice. KEY WORDS myocardial infarction, secondary prevention, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, acute renal failure, acute kidney injury, hyperkalemia, treatment discontinuation, elderly. In 2010,~819,000 acute myocardial infarction (AMI) hospitalizations occurred in the United States, with incidence increasing with patient age. 1 Clinical guidelines recommend angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) for secondary prevention of AMI, based on randomized controlled trial data. 2 Acute renal failure (ARF) and hyperkalemia (HK) are known severe adverse effects after initiating ACEI and ARB treatment. 3 However, like many other interventions, the elderly are not well represented in clinical trials for ACEIs/ARBs, especially among patients older than 75 years. [4] [5] [6] Evidence generated in a tightly controlled trial setting may not reflect clinical practice in real-world settings, particularly for severe adverse events such as ARF and HK. [7] [8] [9] [10] [11] There is a scarcity of knowledge in clinical practice settings on the incidence of ARF and HK and the trajectory of the incidence over time among the elderly who used ACEIs or ARBs after discharge from AMI hospitalization.
Furthermore, identifying factors that increase the risk of ARF and HK in this population is important for therapeutic treatment decision making and monitoring. Several factors such as age, race/ethnicity, sex, and the presence of CKD may be of particular interest. Prior studies showed that increasing age is associated with a higher risk of ARF and HK among the elderly, especially when taking medications that inhibit the renin-angiotensin system. [12] [13] [14] Multiple comorbidities and polypharmacy are common among elderly patients. Differences by sex and racial/ethnic group also exist in the long-term use of secondary prevention therapies for AMI. 15 For example, pharmacologic agents that inhibit the renin-angiotensin system have differential effects in black patients. 3, 16 Studies have suggested that ACEIs may be less effective in black patients than in white patients for blood pressure control and reduction of cardiovascular disease outcomes. 17, 18 ACEIs and ARBs have both been recommended for patients with diabetes mellitus and nephropathy to slow the progression of CKD. 19, 20 However, the risks of ARF and HK are also higher among patients with CKD after ACEI/ARB initiation. 3, 21, 22 This presents a dilemma for clinicians regarding the use of ACEIs/ARBs among patients with CKD after AMI.
Therefore, the objective of this study was to assess the incidence of and risk factors associated with severe adverse events in elderly patients who used ACEIs or ARBs after an AMI. Specifically, we aimed to investigate the incidence of ARF and HK hospitalizations among elderly users of ACEIs or ARBs after hospital discharge for AMI and to examine risk factors associated with ARF and HK hospitalization in elderly patients who used ACEIs or ARBs after AMI in real-world settings. It is possible that clinicians who closely monitor their patients may discontinue or suspend therapy before these adverse events occur if patients present with signs or symptoms related to the adverse effects. Thus we also assessed the secondary outcome of discontinuation or suspension of ACEI/ARB therapy after a visit to a health care provider. These findings will help inform clinicians about which elderly patients should be more closely monitored and situations where ACEI/ARB therapy discontinuation may mitigate the risk of these adverse events.
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Methods
Study Design and Data Sources
The primary data source for this retrospective cohort study was the Centers for Medicare & Medicaid Services Chronic Conditions Data Warehouse (CCW). We used the CCW beneficiary enrollment summary inpatient, outpatient, skilled nursing facility, and Part D prescription drug event research files for the years 2007-2010. This data source contains 100% of the Medicare fee-for-service and prescription claims for beneficiaries hospitalized for an AMI from [2008] [2009] . Other data sources used for these analyses included the 2006-2010 American Community Survey (ACS) of the U.S. Census Bureau 5-year estimates data at the block group level and the Multum Lexicon Drug database. We linked the ACS data to CCW beneficiary files by mapping patients' nine-digit ZIP code to block groups. Multum's drug data were linked to CCW Part D prescription drug event data using National Drug Codes (NDCs). The study was approved by the institutional review board of the University of North Carolina at Chapel Hill (Chapel Hill, NC).
Cohort Selection
The cohort for this study included elderly Medicare patients who were hospitalized for AMI between January 1, 2008, and December 31, 2009. We included patients who were at least 66 years of age at the time of AMI; were continuously enrolled in the Medicare fee-forservice Parts A and B as well as prescription Part D programs at least 12 months before the AMI admission date; and survived for at least 30 days after discharge. In addition, patients with end-stage renal disease at baseline, patients discharged to a hospice, and patients with residence ZIP codes outside of the United States were excluded. Hospitalization with AMI was defined as having International Classification of Diseases, Ninth Revision, Clinical Modification codes of 410.x1 as the primary or secondary discharge codes in Medicare inpatient claims. 15 The first AMI hospitalization in the study period was defined as the index AMI hospitalization for each patient. The consort diagram in Figure A1 (Appendix S1) describes the cohort selection process for these analyses.
Use of ACEIs and ARBs
Prescription claims for ACEIs and ARBs were identified in the CCW prescription Part D event files using NDCs. Patients were defined as ACEI/ ARB users if they had a prescription claim for an ACEI/ARB within 30 days after hospital discharge or had ACEI/ARB medication already on hand from before or during the index AMI hospitalization with sufficient days' supply to last through 30 days after hospital discharge.
Adverse Event Outcome Measures
The primary outcomes for this study were hospitalizations for ARF and HK. These outcomes were identified based on a published algorithm for identifying HK and ARF based on diagnostic codes in claims files. 24, 25 The secondary safety outcome included discontinuation or suspension of ACEI/ARB treatment after a visit to a health care provider. A gap in therapy was defined as a 14-day grace period with no ACEI/ARB refill at the end of a prior prescription supply; this gap was then applied to approximate discontinuation or suspension of treatment due to provider intervention if a patient had a physician office, outpatient, or hospital visit in the period between the last ACEI/ARB fill and the discontinuation date. Anchoring discontinuation or suspension on a provider visit was used to help differentiate normal adherence and persistence patterns from provider-directed discontinuation. Outcome definitions are presented in Table A1 (Appendix S1).
The follow-up period for all events started at whichever of the following events occurred later: day after the first ACEI/ARB fill or discharge date (for patients who had prescription for ACEI/ARB filled before index AMI hospital admission with at least a 30-day supply remaining after hospital discharge). Follow-up ended on either the date of censoring or occurrence of an outcome.
Baseline Characteristics Table 1 presents a select list of baseline characteristics of the study patients, and a full list of variables considered in the analyses is shown in Table A2 (Appendix S1). Baseline patient characteristics were assessed from the Medicare research files during the 12 months before the index hospitalization for AMI. They included comorbidity levels as measured by the Charlson Comorbidity Index (CCI), 26 condition-specific comorbidities, proxy measures for functional limitations, measures of health care utilization, and treatment. Additional covariates included conditions and procedures assessed during the index hospital admission. Indicators of socioeconomic status (income measured at the U.S.
Census block group level and dual eligibility in Medicare and Medicaid) were also included in the model. The primary predictors of interest were age, sex, race/ethnicity, and CKD. All clinical conditions were identified by using algorithms previously validated in the literature. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The complete list of baseline characteristics is presented in Table A2 (Appendix S1).
Statistical Analysis
All patient characteristics were measured categorically and summarized using percentages. Patient characteristics were also stratified by age group, sex, race/ethnicity, and CKD. Unadjusted cumulative incidence curves using methods that accommodate the competing risk of mortality were used for the whole study cohort. We used Gray tests to evaluate differences in the cumulative incidence of outcomes between groups of interest selected a priori. 38 Sensitivity analysis was applied with stratification by ACEIs and ARBs.
Intention-to-treat (ITT) and as-treated (AT) analyses were used to identify the predictors of the safety outcomes. In the ITT analyses, patients were censored at the end of the study period or when they disenrolled from either Medicare fee-for-service or prescription Part D plans. In the AT analyses, patients were additionally censored for switching from target doses in clinical trials to lower doses (or vice versa) or discontinuation. The date of discontinuation was the date of the end of supply for the last dispensed prescription plus a grace period of 14 days. Fine-Gray proportional hazards models with death as competing risk were used to estimate associations between predictive factors and outcomes. 39 To assess unadjusted associations, models where each of the key predictors was the only variable in the model were used. Second, fully adjusted models that estimated the effect of primary factors were run twice, once using the ITT approach and second using the AT method. In addition, we conducted sensitivity analysis by adjusting for the dose of ACEIs/ARBs as a covariate in the regression models. The dose variable was calculated as the average daily dose from the last prescription filled within the 30 days after index AMI hospital discharge. Last, we also assessed the distribution of provider types (cardiologist, primary care physician, and other) for the last physician office, outpatient, or hospital visit before treatment discontinuation.
We used SAS v.9.4 statistical analysis software (SAS Institute Inc., Cary, NC) for all analyses.
Results
Baseline Characteristics
In the final analytical cohort, 101,588 patients met our study protocol eligibility. Overall, 39.8% were aged 75-84 years, and 25.3% of patients were 85 years or older; 59.5% of patients were female, and most were white (85.3%). Approximately 20% of patients had baseline CKD, and 72.4% of patients had a CCI score of at least 1. Table 1 presents data on patient characteristics at baseline and during the index hospital admission. Patient characteristics by age, sex, race/ethnicity and CKD are presented in Tables A3.1-A3.4 (Appendix S1).
Adverse Outcome Events
Cumulative incidence rates for all primary and secondary adverse outcome events are described in Figures 1-4 and Table 2 . Overall, the cumulative incidence rate at 12 months was 2.8% for ARF, 0.5% for HK, and 63.7% for treatment discontinuation. Among the three age groups, the oldest patients (85 yrs or older) had the highest rates of ARF (3.4%) and HK (0.6%). Female patients had slightly but consistently higher incidence rates of ARF (2.9% vs 2.5% at 12 mo), HK (0.49% vs 0.42%), and treatment discontinuation (63.9% vs 63.3%) than male patients. Black patients had the highest rate of ARF at 12 months (4.3%); white patients had the lowest incidence (2.6%). Black (0.84%) and Hispanic (0.80%) patients experienced high rates of HK; white (0.41%) and Asian (0.41%) patients had the lowest rates. The highest 12-month cumulative incidence of discontinuation was among black patients (65.5%) and the lowest among Asians (63.4%). Patients with baseline CKD had considerably higher rates of ARF (6.1% vs 1.9%) at 12 months, HK (0.91% vs 0.35%), and treatment discontinuation (68.4% vs 62.5%) compared with patients without CKD. The Gray's tests comparing the difference in the cumulative incidence of the outcomes among patient subgroups by age, sex, race/ethnicity, and CKD were all statistically significant. In the sensitivity analysis, ARBs only had a slightly higher cumulative incidence of therapy discontinuation than ACEIs but similar incidence rates for ARF or HK hospitalization ( Figure A2 in Appendix S1). Table 3 presents estimated associations between patient characteristics of interest and study adverse outcome events. In the unadjusted ITT and AT analyses, advancing age (75 yrs or older), sex, race/ethnicity (black), and baseline CKD were all associated with notably higher risk of ARF. In the adjusted ITT and AT analyses, advancing age and CKD remained significant factors associated with ARF. Black race was also associated with higher ARF risk in the adjusted ITT models, but it was not statistically significant (hazard ratio [HR] 1.11, 95% confidence interval [CI] 0.94-1.31) in the adjusted AT analysis. HK incidence rates were significantly higher among black and patients of other race/ethnicity compared with white patients in both the unadjusted ITT and AT models; however, the effect was attenuated in the adjusted models. In addition, in multivariable analysis we found that the risk of HK was significantly associated with older age (75 yrs or older) and more prominent at 85 years or older, black race (HR 1.57, 95% CI 1.24-1.98 in ITT), and CKD (HR 1.41, 95% CI 1.11-1.77 in ITT; HR 1.62, 95% CI 1.22-2.16 in AT).
Age, sex, race, and baseline CKD were only weakly associated with treatment discontinuation or suspension in unadjusted analyses. These effects were further attenuated after controlling for comorbidities and clinical characteristics. In the adjusted models, ACEI/ARB treatment discontinuation or suspension was significantly associated with black race in the ITT analysis (HR 1.07, 95% CI 1.04-1.10) but was not statistically significant in AT analysis (HR 1.03, 95% CI 1.00-1.06). Treatment discontinuation or suspension was significantly associated with baseline CKD (HR 1.05, 95% CI 1.02-1.09 in ITT; HR 1.05, 95% CI 1.01-1.09 in AT).
Sensitivity analyses showed very similar and consistent results by additionally adjusting for the dose of ACEIs/ARBs (Table A3 in Appendix S1). Cardiologist accounted for 17.9%, primary care physician 37.9%, and other provider 44.2% of the last provider a patient visited before a treatment discontinuation.
Discussion
Using a large nationally representative cohort of elderly Medicare patients who were treated with ACEIs or ARBs after an AMI hospitalization, we found that the incidence rates of ARF and HK were relatively low, but discontinuation or suspension of therapy after hospital discharge was high: more than 51% within 6 months and 64% at 1 year. The trajectory of the severe adverse events of ARF and HK showed about half the incidence occurred within 6 months after AMI discharge, and the incidence continue to increase in a linear but slower rate thereafter. The trajectory of therapy discontinuation showed a quick increase within 3 months after AMI discharge but plateaued after 6 months. Of all subgroups investigated, patients with CKD before their AMI hospitalization had some of the highest rates of ARF, HK, and ACEI/ARB treatment discontinuation or suspension at 1 year after hospital discharge. Unadjusted ARF rates were also higher among black than white patients and among patients older than 85 years compared with those 66-74 years of age at 12 months after discharge. HK was also more common among black and Hispanic patients than among white patients at 12 months. The unadjusted treatment discontinuation or suspension rate was higher among black patients at 12 months after hospital discharge, but other racial/ethnic groups had similar rates.
The risk of ARF and HK was suggested to be elevated in the elderly population. 12, 13 Several prior studies indicated that the elderly have a higher risk of ARF and suggested that treatment with ACEI/ARBs in this population should be used with caution. 13, 14 Previous studies estimated that as high as 38% of all HK events among hospitalized patients are associated with ACEI/ARB use. 7 Our study showed much lower incidence rates of ARF and HK in the older adults after discharge from the hospital. Our findings are similar to the results from a recent study that also showed low rates of ARF and HK among elderly patients who were treated with aldosterone antagonists. 25 Nonetheless, the rates of treatment discontinuation or suspension after health care provider visits were high, reaching more than 50% at 6 months and more than 60% 1 year after hospitalization. It is possible that these incidence rates were lower in the noninstitutionalized older population because clinicians were managing and monitoring the risk of ARF and HK associated with ACEI/ARB therapy. However, a 50% discontinuation/suspension rate by 6 months after AMI discharge also indicates a potential marked risk for the severe adverse events. The incidence of ARF and HK appeared to increase the most during 45-90 days after hospital discharge. The rate of ACEI/ARB therapy discontinuation/suspension was also high during this time period. However, when the rate of treatment discontinuation/suspension flattened out after 180 days after discharge, the incidence of ARF and HK continued to increase steadily. Based on these findings, clinicians should continue to monitor ACEI/ARB therapy closely in the long term after AMI hospitalization. Our study also found that the primary care physician accounted for 38% of the physician visits before treatment discontinuation. This raises an important question for treatment continuity and coordination, and whether more treatment discontinuation/suspension after primary care physician visit is justified. This question warrants further investigation.
Results from our study suggest that AMI survivors who were 75 years and older or with Figure 4 . Cumulative incidence of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment discontinuation after acute myocardial infarction hospital discharge. CI = confidence interval; CKD = chronic kidney disease; CUM Inc Func = cumulative incidence function; grp = group. CKD may have a considerably increased risk of ARF and HK beyond the 3-month postdischarge period and that these patients should continue to be monitored closely for their ACEI/ARB therapy. Previous studies also showed that patients with baseline CKD were more likely to develop ARF. 40 Our findings are consistent with these earlier reports and indicate that, despite controlling for a variety of other comorbidities and clinical conditions, CKD remains a serious risk factor for ARF. In our adjusted ITT analysis, a higher risk of ARF was also found to be associated with black race. However, in the AT analysis, where treatment discontinuation/suspension were incorporated into the analysis, this effect was attenuated and became statistically insignificant. In other words, among users who can tolerate ACEI/ARBs, no significant difference was found in ARF incidence between black and white patients. Among users who cannot tolerate ACE inhibitors/ARBs, black patients may be more likely to have ARF than white patients. This aligns with our finding that black patients have the highest discontinuation/suspension In the intention-to-treat analyses, patients were censored at the end of the study period or when they disenrolled from either Medicare feefor-service or prescription Part D plans. In the as-treated analyses, patients were additionally censored for switching from an ACEI to ARB (or vice versa) or for treatment discontinuation.
c Fully adjusted models were adjusted for all the variables listed in Table 1. rates. The higher risk of ARF among black patients found in the ITT analysis but not in the AT analysis is worth pondering. One explanation is that among black patients who could not tolerate ACEIs/ARBs, discontinuation or suspension may not have been soon enough or timely enough to prevent their association with events of ARF. Thus the importance of timely discontinuation/suspension as a prevention of severe adverse outcomes needs to be emphasized. A number of previous studies linked ACEI/ ARB treatment to HK. [41] [42] [43] [44] [45] [46] Additional investigations showed that elderly patients treated with potassium-altering therapy, such as ACEIs, are particularly predisposed for development of HK. 12, 47 Our study concurs with earlier findings and shows that advancing age is a key factor contributing to the elevated risk of HK. The results for the association between race and the rates of HK were similar to our findings for ARF: in the ITT analyses, black patients were more likely to experience HK compared with white patients; however, in analyses adjusted for treatment discontinuation/suspension, this effect was attenuated. In addition, in line with previous studies, our analyses indicate that patients with CKD are at higher risk of HK. 42, 44 A notable secondary finding from our study was the fact that, after adjustment for comorbidities, advancing age was not independently associated with treatment discontinuation or suspension. Similarly, no significant differences in the incidence of discontinuation/suspension were found between men and women. Based on our findings, black patients had a slightly higher chance of discontinuation/suspension, a result that agrees with an earlier study that found elderly black patients had higher odds of suboptimal persistence while treated with statins. 48 However, the association between black race and discontinuation/suspension became statistically insignificant in the AT analysis. Our study also pointed out that patients of Hispanic origin have marginally lower rates of therapy discontinuation/suspension than white patients. CKD was also found to be weakly associated with treatment discontinuation.
This study has several limitations. First, variable misclassification was possible using administrative claims data. We followed existing standards using secondary claims data for health services research to mitigate misclassification. Second, time to treatment discontinuation/suspension may have been underestimated if prescriptions were later paid for outside of the Medicare Part D plan after inclusion in the study. However, research has shown that this does not happen often for Medicare beneficiaries, and even when it does, these claims are often adjudicated into Part D records. [49] [50] [51] Medicare patients are also less likely to use medication samples than those in the privately insured population. 52 Third, patients may discontinue or suspend therapy without a clinician asking them to stop, leading to misclassification. In addition, we do not have data on concurrent use of overthe-counter nonsteroidal antiinflammatory drugs with ACEIs/ARBs that may increase the risk of ARF and treatment discontinuation. Further study is warranted to investigate key risk factors for treatment discontinuation.
This study possesses several strengths as well. Our study included a nationally representative sample of all Medicare fee-for-service beneficiaries who had an AMI. To our best knowledge, this is the first study that included a comprehensive examination of the incidence of ARF and HK as well as rates of treatment discontinuation among elderly patients treated with ACEI/ARBs after an AMI.
Conclusion
Our study found a low incidence of ARF and HK among elderly patients treated with ACEIs/ ARBs after AMI hospitalization. Approximately half of the incidence occurred within 6 months after hospital discharge, but the cumulative incidence continued to increase after 6 months. However, timely treatment discontinuation or suspension might prevent a higher rate of occurrence of these serious adverse events. Advancing age was found to be a strong independent factor associated with increased incidence of both ARF and HK, whereas CKD was the most important factor affecting these outcomes as well as treatment discontinuation. Long-term careful monitoring of severe adverse events and timely discontinuation of ACEIs or ARBs among highrisk elderly patients after an AMI is warranted in clinical practice.
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